Dr. William R. Prather, Senior VP of Corporate Development, is the Featured Guest in an Audio Interview at SmallCapVoice.com

Wednesday April 4, 8:31 am ET

About Pluristem

Pluristem Life Systems, Inc. is life sciences driven Company that is developing and commercializing stem cell expansion technology products for the potential treatment of a variety of disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a three-dimensional proprietary bioreactor termed the PluriX(TM) that mimics different naturally occurring physiological environments. Pluristem expects its first product, PLX-BMT, will be involved as an efficient and superior alternative to the standard procedure of bone marrow transplantation (BMT). PLX-BMT is intended to target a critical global shortfall of matched tissue for BMT since BMT is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.

www.pluristem.com

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release, include that we are upgrading and doubling our manufacturing facility to support $200 million in production capacity for PLX - I; that we expect to complete the expansion of the production area as well as the implementation of the GMP controls before the initiation of the Phase I clinical trials which we are expecting to start during 2007; that we are able to increase the production capability of this new facility by another 300% very quickly; that this enables us to scale our production as we gain market share and still keep our expenses under control. Factors that could prevent our forward-looking statements from being achieved include that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.

For more information visit our website at www.pluristem.com